MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay— 510(k) DEN170058
UnknownMemorial Sloan-Kettering Cancer Center
FDA 510(k) clearance DEN170058 for MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets):a Hybridization-Capture Based Next Generation Sequencing Assay, Unknown on 2017-11-15. Applicant: Memorial Sloan-Kettering Cancer Center.
Clearance details
- Applicant
- Memorial Sloan-Kettering Cancer Center
- Product code
- Code PZM
- Advisory panel
- Pathology
- Date received
- Decision date
- Decision
- Unknown
- Clearance type
- Direct
- Location
- New York, NY, US
Data sourced from openFDA. This site is unofficial and independent of the FDA.